NovaBridge Biosciences names Srishti Gupta as CEO, succeeding Sean Fu

NovaBridge Biosciences announced the appointment of Srishti Gupta, MD MPP as Chief Executive Officer and a member of the Board of Directors, effective July 1, 2026.¹ Xi-Yong (Sean) Fu, the outgoing CEO, will step down to pursue other opportunities and will support the company in an advisory capacity during the transition.¹ Per the 6-K filing, Gupta succeeds Fu, who tendered his resignation as CEO and board member effective June 30, 2026, a departure the company said was not the result of any disagreement over operations, policies or practices.¹

Gupta served as CEO of Idorsia Pharmaceuticals Ltd (SIX: IDIA) from July 2025 to March 2026, and as a board member from 2021 to March 2026.¹ The company's press release characterized her tenure there as involving a full operational and financial turnaround after she was appointed to lead the company following four years on its board.¹

Earlier in her career, Gupta spent 2003 to 2021 at McKinsey & Company, where she held the position of Senior Expert and Global Director, and led the firm's Global Health Practice for over a decade.¹

She currently holds other board roles: she has served on the board of Santhera Pharmaceuticals (SIX: SANN) since May 2026,¹ and previously served on the board of Invivyd, Inc. (Nasdaq: IVVD) from May 2024 to May 2025, chairing its Compensation Committee.¹

The filing also disclosed board and management changes beyond the CEO transition: Emmett T. Cunningham, Jr., M.D., Ph.D., MPH and Sean Cao, Ph.D. tendered resignations as board members effective June 30, 2026,¹ and Mark Hagler resigned as President effective July 1, 2026, while remaining Chief Commercial Officer.¹

The company said as CEO, Gupta will focus on advancing givastomig toward registration, expanding the ophthalmology franchise under Visara, and establishing strategic partnerships.¹